Correlation between time to progression and overall survival in patients with metastatic breast cancer

被引：1
|
作者：
Sherrill, B.
Hirst, C.
Wu, Y.
Amonkar, M. M.
Stein, S.
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] RTI Hlth Solut, Manchester, Lancs, England
[3] GlaxoSmithKline Inc, Collegeville, PA USA
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)68914-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A123 / A124
页数：2
相关论文
共 50 条
  • [21] Disease progression as a predictor of overall survival in metastatic breast cancer: a meta-analysis
    Sherrill, B.
    Amonkar, M.
    Wu, Y.
    Hirst, C.
    Stein, S.
    Walkers, M.
    Cuzick, J.
    EJC SUPPLEMENTS, 2008, 6 (07): : 216 - 216
  • [22] Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study
    Valachis, Antonis
    Carlqvist, Peter
    Ma, Yuanjun
    Szilcz, Mate
    Freilich, Jonatan
    Vertuani, Simona
    Holm, Barbro
    Lindman, Henrik
    BRITISH JOURNAL OF CANCER, 2022, 127 (04) : 720 - 725
  • [23] Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study
    Antonis Valachis
    Peter Carlqvist
    Yuanjun Ma
    Máté Szilcz
    Jonatan Freilich
    Simona Vertuani
    Barbro Holm
    Henrik Lindman
    British Journal of Cancer, 2022, 127 : 720 - 725
  • [24] Estimating changes in overall survival using progression-free survival in metastatic breast and colorectal cancer
    Bowater, Russell J.
    Lilford, Philippa E.
    Lilford, Richard J.
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2011, 27 (03) : 207 - 214
  • [25] Circulating tumor cells are a reliable predictor of progression free survival and overall survival during therapy of patients with metastatic breast cancer
    Hayes, DF
    Miller, MC
    Cristofanilli, M
    Ellis, MJ
    Stopek, A
    Allard, WJ
    Matera, J
    Doyle, GV
    Terstappen, LWWM
    Budd, GT
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S225 - S225
  • [26] Overall survival of metastatic breast cancer patients - data from the PRAEGNANT breast cancer registry
    Taran, Florin-Andrei
    Fasching, Peter A.
    Volz, Bernhard
    Huober, Jens
    Overkamp, Friedrich
    Kolberg, Hans Christian
    Hadji, Peyman
    Tesch, Hans
    Haeberle, Lothar
    Ettl, Johannes
    Lux, Michael P.
    Hartkopf, Andreas D.
    Lueftner, Diana
    Wallwiener, Markus
    Mueller, Volkmar
    Beckmann, Matthias W.
    Belleville, Erik
    Wimberger, Pauline
    Hielscher, Carsten
    Geberth, Matthias
    Fersis, Nikos
    Abenhardt, Wolfgang
    Kurbacher, Christian
    Wuerstlein, Rachel
    Thomssen, Christoph
    Untch, Michael
    Janni, Wolfgang
    Fehm, Tanja N.
    Wallwiener, Diethelm
    Brucker, Sara Y.
    Schneeweiss, Andreas
    CANCER RESEARCH, 2018, 78 (04)
  • [27] Correlation between alternative endpoints and overall survival in metastatic colorectal cancer patients eligible to a maintenance strategy
    Turpin, A.
    Paget-Bailly, S.
    Ploquin, A.
    Hollebecque, A.
    Dominguez, S.
    Bonnetain, F.
    El Hajbi, F.
    Hebbar, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
    Cicero, Giuseppe
    De Luca, Rossella
    Dieli, Francesco
    ONCOTARGETS AND THERAPY, 2018, 11 : 3059 - 3063
  • [29] Association between bisphosphonate use in metastatic breast cancer (MBC) and overall survival
    Mathew, A.
    Rosenzweig, M. Q.
    Brufsky, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [30] Evaluation of overall survival (OS), progression-free survival (PFS), or time to progression (TTP) in systematic review of randomized clinical trials (RCT) in patients with metastatic breast cancer (MBC)
    Mukonje, Terence
    Santana-Davila, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345